Pharmena S.A.

WAR:PHR Poland Biotechnology
Market Cap
$8.84 Million
zł36.75 Million PLN
Market Cap Rank
#33460 Global
#312 in Poland
Share Price
zł3.30
Change (1 day)
-3.79%
52-Week Range
zł2.55 - zł4.58
All Time High
zł28.01
Categories
Companies in Poland Biotechnology
About

Pharmena S.A., a biotechnology company, manufactures and sells active ingredients in various areas of medicines in Poland and internationally. The company offers dermatological cosmetics, including face, hair, and body care products, as well as dietary supplement. It offers its products under the Menavitin, Dermena, Allerco, and Thermi names. Pharmena S.A. was founded in 2002 and is based in Lódz… Read more

Pharmena S.A. (PHR) - Net Assets

Latest net assets as of September 2025: zł10.54 Million PLN

Based on the latest financial reports, Pharmena S.A. (PHR) has net assets worth zł10.54 Million PLN as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (zł11.39 Million) and total liabilities (zł850.00K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets zł10.54 Million
% of Total Assets 92.54%
Annual Growth Rate -1.49%
5-Year Change N/A
10-Year Change 43.22%
Growth Volatility 65.79

Pharmena S.A. - Net Assets Trend (2008–2024)

This chart illustrates how Pharmena S.A.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Pharmena S.A. (2008–2024)

The table below shows the annual net assets of Pharmena S.A. from 2008 to 2024.

Year Net Assets Change
2024-12-31 zł12.42 Million -44.12%
2023-12-31 zł22.23 Million +427.24%
2022-12-31 zł-6.79 Million -32.63%
2021-12-31 zł-5.12 Million -1371.55%
2020-12-31 zł-348.00K -106.97%
2019-12-31 zł5.00 Million +158.06%
2018-12-31 zł1.94 Million -45.63%
2017-12-31 zł3.56 Million -40.08%
2016-12-31 zł5.94 Million -31.47%
2015-12-31 zł8.67 Million -33.72%
2014-12-31 zł13.08 Million -27.51%
2013-12-31 zł18.05 Million +101.02%
2012-12-31 zł8.98 Million -45.43%
2011-12-31 zł16.45 Million +3.44%
2010-12-31 zł15.91 Million -1.56%
2009-12-31 zł16.16 Million +2.37%
2008-12-31 zł15.78 Million --

Equity Component Analysis

This analysis shows how different components contribute to Pharmena S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 270.1% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock zł1.11 Million 8.97%
Other Comprehensive Income zł6.00K 0.05%
Other Components zł12.56 Million 101.14%
Total Equity zł12.42 Million 100.00%

Pharmena S.A. Competitors by Market Cap

The table below lists competitors of Pharmena S.A. ranked by their market capitalization.

Company Market Cap
RELIANCE STEEL & AL (RS6.SG)
STU:RS6
 		$2.62 Million
Unifin Financiera S. A. B. de C. V
MX:UNIFINA
 		$2.62 Million
Patriot Resources Ltd
AU:PAT
 		$2.62 Million
RUBIX Resources Ltd
AU:RB6
 		$2.62 Million
M8 Sustainable Ltd
AU:M8S
 		$2.62 Million
Raize Servicos de Gestao SA
LS:MLRZE
 		$2.62 Million
SEED INNOVATIONS LTD.
F:LYZ1
 		$2.62 Million
ONE MEDIA IP GRP LS-005
F:1M9
 		$2.62 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Pharmena S.A.'s equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 22,521,000 to 12,420,000, a change of -10,101,000 (-44.9%).
  • Net loss of 1,262,000 reduced equity.
  • Dividend payments of 9,467,000 reduced retained earnings.
  • Other comprehensive income decreased equity by 211,001.
  • Other factors increased equity by 839,001.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income zł-1.26 Million -10.16%
Dividends Paid zł9.47 Million -76.22%
Other Comprehensive Income zł-211.00K -1.7%
Other Changes zł839.00K +6.76%
Total Change zł- -44.85%

Book Value vs Market Value Analysis

This analysis compares Pharmena S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 2.96x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has increased from 1.46x to 2.96x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2008-12-31 zł2.25 zł3.30 x
2009-12-31 zł2.31 zł3.30 x
2010-12-31 zł2.27 zł3.30 x
2011-12-31 zł2.35 zł3.30 x
2012-12-31 zł1.22 zł3.30 x
2013-12-31 zł1.96 zł3.30 x
2014-12-31 zł1.42 zł3.30 x
2015-12-31 zł0.94 zł3.30 x
2016-12-31 zł0.65 zł3.30 x
2017-12-31 zł0.40 zł3.30 x
2018-12-31 zł0.22 zł3.30 x
2019-12-31 zł0.51 zł3.30 x
2020-12-31 zł-0.01 zł3.30 x
2021-12-31 zł-0.44 zł3.30 x
2022-12-31 zł-0.58 zł3.30 x
2023-12-31 zł2.02 zł3.30 x
2024-12-31 zł1.12 zł3.30 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Pharmena S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -10.16%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -470.90%
  • • Asset Turnover: 0.02x
  • • Equity Multiplier: 1.09x
  • Recent ROE (-10.16%) is above the historical average (-18.07%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2008 3.87% 16.05% 0.23x 1.05x zł-966.94K
2009 4.78% 12.09% 0.37x 1.06x zł-844.23K
2010 0.78% 1.61% 0.46x 1.06x zł-1.47 Million
2011 3.70% 6.94% 0.49x 1.10x zł-1.04 Million
2012 -45.66% -44.91% 0.79x 1.29x zł-5.00 Million
2013 -15.75% -20.11% 0.69x 1.14x zł-4.65 Million
2014 -31.23% -28.92% 0.84x 1.29x zł-5.39 Million
2015 -41.70% -20.69% 1.15x 1.75x zł-4.48 Million
2016 -28.00% -10.46% 1.11x 2.40x zł-2.26 Million
2017 -67.09% -19.10% 1.13x 3.12x zł-2.75 Million
2018 -22.95% -3.40% 1.92x 3.52x zł-637.50K
2019 -186.32% -86.25% 0.95x 2.28x zł-10.09 Million
2020 0.00% -69.37% 0.91x 0.00x zł-6.88 Million
2021 0.00% -30.18% 1.36x 0.00x zł-4.11 Million
2022 0.00% -525.08% 0.02x 0.00x zł-921.00K
2023 128.51% 294.21% 0.41x 1.07x zł26.69 Million
2024 -10.16% -470.90% 0.02x 1.09x zł-2.50 Million

Industry Comparison

This section compares Pharmena S.A.'s net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $94,217,323
  • Average return on equity (ROE) among peers: -48.70%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Pharmena S.A. (PHR) zł10.54 Million 3.87% 0.08x $2.62 Million
Bioceltix S.A. (BCX) $1.91 Million -83.78% 0.69x $71.31 Million
Bioton S.A. (BIO) $619.64 Million 5.47% 0.40x $42.39 Million
Captor Therapeutics S.A. (CTX) $124.20 Million -26.23% 0.16x $69.93 Million
Mabion S.A. (MAB) $-54.16 Million 0.00% 0.00x $31.56 Million
Molecure S.A. (MOC) $126.45 Million -10.71% 0.09x $21.11 Million
Nanogroup SA (NNG) $8.37 Million -119.60% 1.43x $12.30 Million
PolTREG S.A. (PTG) $12.83 Million -6.84% 0.27x $16.72 Million
Pure Biologics Spólka Akcyjna (PUR) $7.21 Million -65.22% 2.02x $2.90 Million
Ryvu Therapeutics SA (RVU) $1.50 Million -131.36% 5.84x $100.54 Million